A Case of Bilateral Uveitis and Papillitis in a Patient Treated with Pembrolizumab

Abstract

In current clinical practice, many new drugs are being approved, requiring better characterization of the prevalence, onset, and nature of adverse events in order to aid development of effective management strategies. Ophthalmologists should keep in mind that drugs are always a possible cause of ocular inflammation in patients presenting with uveitis.